• We showed that activation of the ATM

  2024-02-19

  

  We showed that activation of the ATM/ATR pathway leads to over-replication through suppression of CDK1 activity, consistent with previous findings that suppression of CDK1 activity is involved in the polyploidization of megakaryocyte and trophoblast cells [36], [37], [38], [39]. Suppression of CDK1

• Most of lipid lowering agents

  2024-02-19

  

  Most of lipid-lowering agents have many therapeutic problems with severe side effects, while dietary fibers as lipid lowering therapy are safer. Chitosan (CS) is a dietary fiber biodegradable, biocompatible and has many health benefits including wound healing, antiinflammatory, anti-cancers, immune-

• To circumvent these issues multiple

  2024-02-19

  

  To circumvent these issues, multiple approaches have been developed that target small fractions of the genome, thus reducing the sequencing burden (Dostie et al., 2006; Fullwood et al., 2009; Mumbach et al., 2016). Application of one such approach, chromosome conformation capture carbon copy (5C), w

• Furthermore a study in Drosophila has reported that

  2024-02-19

  

  Furthermore, a study in Drosophila has reported that Dpatj can interact directly with Dmpar6 providing another potential mechanism linking the Crb to the Par complex [163]. In contrast, Wang et al. in 2004 [63] have shown that at least in MDCK epithelial cells, PAR6 binding to PALS1 interferes with

• While we chose to divide our etiologies into

  2024-02-19

  

  While we chose to divide our etiologies into three categories, it should be noted that such division has certain limitations. Even though URIs and the common cold are considered mainly viral in origin and rhinosinusitis mainly bacterial in origin,26, 27 there is considerable overlap between these co

• A phase I trial has recently evaluated

  2024-02-18

  

  A phase I trial has recently evaluated enzalutamide, an anti-androgen agent, in patients with ER- and AR-positive advanced BC to estimate safety and tolerability of enzalutamide therapy alone or in association to anastrozole, exemestane or fulvestrant [65]. The results of major clinical trials with

• To date attention has been directed towards

  2024-02-18

  

  To date, attention has been directed towards new molecular targets in luminal phenotype (ER-positive), such as CDK4/6 and, to a lesser extent, androgen receptor (AR) pathways [8]. While the role of CDK4/6 has been elucidated and their inhibitors have shown a benefit in luminal BC, the role of AR in

• The increased occurrence of ARIA E

  2024-02-18

  

  The increased occurrence of ARIA-E in APOE ε4 carriers in phase 2 studies resulted in separate protocols for carriers and noncarriers in the subsequent phase 3 studies. Two 18-month trials comprising 1121 carriers and 1331 noncarriers with mild to moderate AD tested doses of bapineuzumab that varied

• ATM is generally regarded to

  2024-02-10

  

  ATM is generally regarded to be the principal mediator of the G1 Propidium iodide checkpoint, whereas the induction of the intra-S-phase and G2/M checkpoints are usually primarily related to ATR function. However, several studies have demonstrated that, depending on the cellular context and type of

• Another interesting aspect of neutralizing AP is the

  2024-02-10

  

  Another interesting aspect of neutralizing AP-1 is the inhibition of interactions between AP-1 and Smad proteins, which synergize to activate the TGF-β1-responsive genes involved in hypertrophic growth of the heart muscle and in the development of cardiac fibrosis. Through preventing AP-1 activation

• Protein arrays provide a new approach for the

  2024-02-10

  

  Protein arrays provide a new approach for the identification of substrates for several protein-modifying enzymes. For example, protein kinase substrate identification, which constitutes an important aspect of pathway mapping because of the prevalence of these substrates in biological pathways. MacBe

• Annexin V-Cy5 Apoptosis Kit ALK fusion positive NSCLC is cli

  2024-02-09

  

  ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective

• COPD is almost unheard of in

  2024-02-09

  

  COPD is almost unheard of in individuals less than 40 years of age (even among heavy smokers), 1 in 10 lifetime never-smokers and 1 in 3 develop COPD by age 75 [26], unquestionably, COPD is an age-related disorder. This notion of accelerated ageing of COPD is supported by animal models, which demons

• Polycyclic aromatic hydrocarbons PAHs are abundant environme

  2024-02-09

  

  Polycyclic aromatic hydrocarbons (PAHs) are abundant environmental contaminants that are produced by the incomplete combustion of organic matter, combustion engines, residential heating, lumiracoxib burning, and industrial activities (Gelboin, 1980; Phillips, 1999, Phillips, 2002). Some PAHs have b

• (+)-Catechin hydrate receptor In particular we focused our a

  2024-02-09

  

  In particular, we focused our attention on beta2 adrenergic receptors, since their commercial inhibitors are effective in lowering IOP, the primary indication of glaucoma. The hypotensive action of a commercial sequence of beta2 adrenergic receptor siRNA was tested in rabbits. The results confirmed

15904 records 194/1061 page Previous Next First page 上5页 191192193194195 下5页 Last page